Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration

Table 2 Treatment and clinical outcomes of EIB and TB-AOI cases - Alberta, 2004–14

	EIB (n = 21)	TB-AOI (n = 20)
Type of treatment
Directly observed	13	5
Self-administered	8	15
Duration ATT – month
Median (range)	6 (1–9)	6 (1–9)
Severe adverse drug events^a (ADE)– no. (%)	3 (14)	2 (10)
Last clinical assessment outcome – no. (%)	n = 20	n = 6
Resolved	14 (70)	0
Improved	2 (10)	3 (50)
No-change	4 (20)	3 (50)

^aMajor ADE = treatment discontinued (no.) - hepatotoxicity (1), rash (1), GI upset (2), severe fatigue (1)

ISSN: 1471-2334